After a visit of the PLN Foundation to the Mount Sinai hospital in New York City, the contact was made with Litsa Kranias. Dr. Kranias is the discoverer and the “mother” of the PLN disorder, and has been playing a very important role for many years already in the Phospholamban studies.
Dr. Evangelia (Litsa) Kranias was born in Thessaloniki, Greece. After her study in America at the university of Chicago, she started her career at the university of Cincinnati, where she currently holds the position of Director of Cardiovascular Biology. Litsa leads an internationally recognized research program in Cardiovascular Biology which provides fundamental insights into the regulation of the calcium cycle in a normal and a defective heart.
PLN studies: her discoveries…
Litsa provided the first evidence that Phospholamban plays an important role in regulating cardiac contractility: by adjusting the levels of the PLN, it is possible to influence the pump operation of the heart.
Litsa also expanded her discoveries to the clinical area and made it clear that the treatment of calcium binding proteins is crucial in the deteriorating function of the human heart causing heart failure.
Litsa has further identified genetic variations in the cycle of calcium binding proteins which may bring significant changes to the clinical timeline of heart failure.
International PLN network
Dr. Litsa Kranias belongs to the group of dedicated PLN specialists and collaborates with international scientific Institutes. For 25 years now, Litsa shares a friendly collaboration with Dr. R.J. Hajjar (Mount Sinai hospital, NYC), who has made progress in 2015 in molecular medicine: he has corrected the heart failure gene disorder in human heart cells. This research now continues with in-vivo trials on animals and pre-clinical studies.